Project Grant R44HL123069

Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital $247,500 under the Cardiovascular Diseases Research program (CFDA 93.837) to validate a positron emission tomography (PET) imaging probe targeting CD206-positive macrophages for idiopathic pulmonary fibrosis (IPF) diagnosis and monitoring. The project, which commenced August 15, 2025 and concludes July 31, 2027, aims to develop and validate a PET imaging agent that shares...

Preclinical Evaluation of F-18 PET Radiotracers for Mu Opioid Receptor Imaging Yale University received a $462,625 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct preclinical evaluation of fluorine-18 (F-18) positron emission tomography (PET) radiotracers for mu opioid receptor (MOR) imaging. The award, which commenced July 1, 2026 and concludes June 30, 2028, supports research designed to advance the...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Washington University a Project Grant totaling $768,567 (awarded September 15, 2025; completion date August 31, 2029) under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate positron emission tomography (PET) imaging technology for early detection of chemotherapy-induced cardiotoxicity. The primary deliverable is the advancement of 68GA-GALMYDAR, a novel PET tracer...

Federal Project Grant Award Summary The University of Pittsburgh received a $1,559,091 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 10, 2026, with completion targeted for April 30, 2028. This award supports the development and validation of a novel positron emission tomography (PET) imaging approach targeting chemokine-like receptor 1 (CMKLR1) to noninvasively monitor macrophage-driven...

Federal Project Grant Award Summary Yale University received a $445,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2026, through July 31, 2028. The award funds development and application of Deuterium Metabolic Imaging (DMI) technology to non-invasively map cardiac glucose metabolism and detect ischemic conditions in the heart. DMI uses deuterated compounds (such as...

Federal Project Grant Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received an $848,141 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2026, with a completion date of March 31, 2031. The award funds research to develop and validate cardiac magnetic resonance (CMR) imaging-based diagnostic criteria for coronary microvascular dysfunction (MVD)—a condition affecting up to...

This Project Grant from the National Heart, Lung and Blood Institute, part of the Department of Health and Human Services, was awarded under the Cardiovascular Diseases Research program (CFDA 93.837) to develop clinical software to support quantitative analysis and interpretation of myocardial contrast echocardiography (MCE) data. Narnar, LLC received $757,197 to create software modules that enhance MCE's ability to identify coronary microvascular dysfunction (MVD). The software will average...

Federal Project Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB), operating under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), awarded $312,165 to Lawrence Berkeley National Laboratory for the development of Time-of-Flight Multi-Photon Emission Tomography (TOF-MPET), a novel nuclear imaging modality designed to address critical limitations in radiopharmaceutical therapy (RPT) imaging....

This $384,863 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program supports research to develop a novel radiotracer imaging agent for detecting Gram-positive bacterial infections associated with implanted medical devices. The key products and services to be delivered include: In vitro testing of a bivalent radiotracer agent...

Federal Project Grant Award Summary Massachusetts General Hospital's Research Management Division received $186,840 in federal funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for a project titled "Advanced Analysis of High-Resolution Cardiac Diffusion Tensor Images." The award was obligated on July 3, 2026, with a completion date of June 30, 2031. The research deliverables focus on advancing diffusion...